Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
AE Management With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Evolving and Current Standards of Care for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Prognosis and Survival Outcomes for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
August 8th 2023Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Potential Approaches to Treatment Switching in HR+/HER2- mBC
August 1st 2023Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
August 1st 2023Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
July 25th 2023Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.